265 related articles for article (PubMed ID: 28750271)
21. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
[TBL] [Abstract][Full Text] [Related]
22. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
23. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Raymond E; Alexandre J; Faivre S; Goldwasser F; Besse-Hammer T; Gianella-Borradori A; Jego V; Trandafir L; Rejeb N; Awada A
Invest New Drugs; 2014 Feb; 32(1):94-103. PubMed ID: 23539344
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J; O'Reilly EM; Middleton MR; Chau I; Hochster H; Fielding A; Burke W; Burris H
Ann Oncol; 2015 Apr; 26(4):804-811. PubMed ID: 25573533
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
[TBL] [Abstract][Full Text] [Related]
27. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Sabatier R; Vicier C; Garnier S; Guille A; Carbuccia N; Isambert N; Dalenc F; Robert M; Levy C; Pakradouni J; Adelaïde J; Chaffanet M; Sfumato P; Mamessier E; Bertucci F; Goncalves A
Mol Oncol; 2022 May; 16(10):2057-2070. PubMed ID: 35122700
[TBL] [Abstract][Full Text] [Related]
29. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
Aspeslagh S; Shailubhai K; Bahleda R; Gazzah A; Varga A; Hollebecque A; Massard C; Spreafico A; Reni M; Soria JC
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1257-1265. PubMed ID: 28424962
[TBL] [Abstract][Full Text] [Related]
30. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
31. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Aglietta M; Barone C; Sawyer MB; Moore MJ; Miller WH; Bagalà C; Colombi F; Cagnazzo C; Gioeni L; Wang E; Huang B; Fly KD; Leone F
Ann Oncol; 2014 Sep; 25(9):1750-1755. PubMed ID: 24907635
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
33. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Sausville E; Lorusso P; Carducci M; Carter J; Quinn MF; Malburg L; Azad N; Cosgrove D; Knight R; Barker P; Zabludoff S; Agbo F; Oakes P; Senderowicz A
Cancer Chemother Pharmacol; 2014 Mar; 73(3):539-49. PubMed ID: 24448638
[TBL] [Abstract][Full Text] [Related]
34. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
36. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky MP; Rescigno P; Bianchini D; Zafeiriou Z; Mehra N; Mateo J; Michalarea V; Riisnaes R; Crespo M; Figueiredo I; Miranda S; Nava Rodrigues D; Flohr P; Tunariu N; Banerji U; Ruddle R; Sharp A; Welti J; Lambros M; Carreira S; Raynaud FI; Swales KE; Plymate S; Luo J; Tovey H; Porta N; Slade R; Leonard L; Hall E; de Bono JS
Ann Oncol; 2020 May; 31(5):619-625. PubMed ID: 32205016
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
38. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
39. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Fountzilas C; Adjei A; Opyrchal M; Evans R; Ghasemi M; Attwood K; Groman A; Bshara W; Goey A; Wilton J; Ma WW; Iyer R
Int J Cancer; 2021 Dec; 149(12):2063-2074. PubMed ID: 34319586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
